基础医学与临床 ›› 2024, Vol. 44 ›› Issue (5): 665-672.doi: 10.16352/j.issn.1001-6325.2024.05.0665

• 研究论文 • 上一篇    下一篇

miR-135a-5p通过调控CXCL12表达降低吗啡耐受

何华美1, 陆巍2*   

  1. 1.贵州医科大学 麻醉学院,贵州 贵阳 550000;
    2.贵州医科大学附属医院 疼痛科,贵州 贵阳 550000
  • 收稿日期:2023-12-11 修回日期:2024-03-19 出版日期:2024-05-05 发布日期:2024-04-23
  • 通讯作者: *adjqy@126.com
  • 基金资助:
    贵州省卫生健康委科学技术项目(gzwkj2023-395)

miR-135a-5p alleviates morphine tolerance by targeting the regulation of CXCL12 expression

HE Huamei1, LU Wei2*   

  1. 1. College of Anesthesiology, Guizhou Medical University, Guiyang 550000;
    2. Department of Pain, Affiliated Hospital of Guizhou Medical University, Guiyang 550000,China
  • Received:2023-12-11 Revised:2024-03-19 Online:2024-05-05 Published:2024-04-23
  • Contact: *adjqy@126.com

摘要: 目的 研究miR-135a-5p调控CXCL12对C57BL/6J小鼠吗啡耐受的影响。方法 将64只小鼠随机分为:对照(NS)组、吗啡耐受(MT)组、CXCL12沉默(CXCL12-siRNA)组、沉默阴性对照(NC-siRNA)组、miR-135a-5p 激动剂(miR-agomir)组、激动剂阴性对照(miR-NC)组、miR-135a-5p 激动剂+CXCL12过表达(miR-agomir+LV-CXCL12)组、miR-135a-5p 激动剂+过表达阴性对照(miR-agomir+LV-control)组。通过皮下注射给药建立吗啡镇痛耐受模型,采用温水甩尾法测定各组小鼠给药前和给药后的热甩尾时间(TL);造模结束后麻醉处死小鼠并取L4~L5脊髓组织,RT-qPCR检测miR-135a-5p 及CXCL12 mRNA的表达,Western blot检测CXCL12蛋白的表达,双荧光素酶报告基因实验检测miR-135a-5p、CXCL12的靶向关系。结果 1)成功建立吗啡耐受小鼠模型,与NS组相比,MT组 CXCL12 mRNA及蛋白表达显著升高(P<0.05),miR-135a-5p显著下调(P<0.05)。2)沉默Cxcl12及过表达miR-135a-5p均提高吗啡耐受小鼠热痛阈值,显著减缓吗啡耐受的发生发展(P<0.05)。3)与miR-NC相比,miR-agomir组CXCL12 mRNA及蛋白表达均下降(P<0.05)。4)双荧光素酶报告基因实验显示miR-135a-5p靶向作用于Cxcl12。5)过表达CXCL12可逆转miR-135a-5p对吗啡耐受小鼠的热痛保护作用。结论 miR-135a-5p通过靶向抑制CXCL12表达进而缓解吗啡耐受的形成。

关键词: 吗啡耐受, CXC趋化因子配体12(CXCL12), 微小RNA, miR-135a-5p

Abstract: Objective Investigating the effect of miR-135a-5p in regulating of CXCL12 on the formation of morphine tolerance in C57BL/6J mice. Methods Totally 64 mice were randomly divided into the following groups: control (NS) group, morphine tolerance (MT) group, CXCL12 inhibitor (CXCL12-siRNA) group, inhibitor negative control (NC-siRNA) group, miR-135a-5p agonist (miR-agomir) group, agonist negative control (miR-NC) group, miR-135a-5p agonist+CXCL12 overexpression (miR-agomir+LV-CXCL12) group, and miR-135a-5p agonist+CXCL12 over-expression negative control (miR-agomir+LV-control) group. Morphine tolerance models were established by subcutaneous injection. The tail-flick test was used to measure the thermal tail-flick latency (TL) before and after drug administration in each group. After modeling, the mice were euthanized under anesthesia, and L4~L5 spinal cord tissues were collected. RT-qPCR method was used to detect the expression of miR-135a-5p and CXCL12 mRNA, Western blot was used to detect the expression of CXCL12 proteins, and a dual luciferase reporter gene assay was used to detect the targeting relationship between miR-135a-5p and CXCL12. Results 1)The morphine-tolerant mouse model demonstrated a significant increase in CXCL12 mRNA and protein expression(P<0.05) and a significant downregulation of miR-135a-5p (P<0.05) compared to the NS group. 2)Silencing Cxcl12 and over-expression of miR-135a-5p both increased the thermal pain threshold in morphine-tolerant mice, significantly slowed down the occurrence and progression of morphine tolerance. 3)Compared to the miR-NC group, the miR-agomir group showed a decrease in both CXCL12 mRNA and protein expression(P<0.05). 4)Dual-luciferase reporter gene experiments demonstrated that miR-135a-5p was targeted at Cxcl12. 5)Over-expression of CXCL12 reversed the thermal pain-protective effect of miR-135a-5p in morphine-tolerant mice. Conclusions It is demonstrated by the results above that miR-135a-5p alleviates the formation of morphine tolerance by suppressing the expression of CXCL12.

Key words: morphine tolerance, C-X-C motif chemokine ligand 12(CXCL12), microRNA, miR-135a-5p

中图分类号: